169 related articles for article (PubMed ID: 24173284)
1. Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis.
Slee EA; Lu X
Sci Rep; 2013 Oct; 3():3105. PubMed ID: 24173284
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo.
Slee EA; Benassi B; Goldin R; Zhong S; Ratnayaka I; Blandino G; Lu X
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19479-84. PubMed ID: 20962274
[TBL] [Abstract][Full Text] [Related]
3. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas.
Hoogervorst EM; Bruins W; Zwart E; van Oostrom CT; van den Aardweg GJ; Beems RB; van den Berg J; Jacks T; van Steeg H; de Vries A
Cancer Res; 2005 May; 65(9):3610-6. PubMed ID: 15867355
[TBL] [Abstract][Full Text] [Related]
4. The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.
Fifield BA; Qemo I; Kirou E; Cardiff RD; Porter LA
Breast Cancer Res; 2019 Dec; 21(1):140. PubMed ID: 31829284
[TBL] [Abstract][Full Text] [Related]
5. p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis.
Yamamoto M; Tsukamoto T; Sakai H; Shirai N; Ohgaki H; Furihata C; Donehower LA; Yoshida K; Tatematsu M
Carcinogenesis; 2000 Oct; 21(10):1891-7. PubMed ID: 11023548
[TBL] [Abstract][Full Text] [Related]
6. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity.
Turenne GA; Price BD
BMC Cell Biol; 2001; 2():12. PubMed ID: 11483158
[TBL] [Abstract][Full Text] [Related]
9. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
10. p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling.
Matsumoto A; Takeishi S; Nakayama KI
Blood; 2014 May; 123(22):3429-39. PubMed ID: 24652995
[TBL] [Abstract][Full Text] [Related]
11. Hipk2 cooperates with p53 to suppress γ-ray radiation-induced mouse thymic lymphoma.
Mao JH; Wu D; Kim IJ; Kang HC; Wei G; Climent J; Kumar A; Pelorosso FG; DelRosario R; Huang EJ; Balmain A
Oncogene; 2012 Mar; 31(9):1176-80. PubMed ID: 21785465
[TBL] [Abstract][Full Text] [Related]
12. The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation.
Ponnamperuma RM; King KE; Elsir T; Glick AB; Wahl GM; Nister M; Weinberg WC
J Pathol; 2009 Oct; 219(2):263-74. PubMed ID: 19718706
[TBL] [Abstract][Full Text] [Related]
13. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice.
Johnson TM; Attardi LD
Cell Death Differ; 2006 Jun; 13(6):902-8. PubMed ID: 16557272
[No Abstract] [Full Text] [Related]
14. Oncogene-induced senescence as an initial barrier in lymphoma development.
Braig M; Lee S; Loddenkemper C; Rudolph C; Peters AH; Schlegelberger B; Stein H; Dörken B; Jenuwein T; Schmitt CA
Nature; 2005 Aug; 436(7051):660-5. PubMed ID: 16079837
[TBL] [Abstract][Full Text] [Related]
15. E2F1 and E2F2 prevent replicative stress and subsequent p53-dependent organ involution.
Iglesias-Ara A; Zenarruzabeitia O; Buelta L; Merino J; Zubiaga AM
Cell Death Differ; 2015 Oct; 22(10):1577-89. PubMed ID: 25656653
[TBL] [Abstract][Full Text] [Related]
16. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
17. PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.
Rybanska I; Ishaq O; Chou J; Prakash M; Bakhsheshian J; Huso DL; Franco S
Oncogene; 2013 Apr; 32(14):1761-71. PubMed ID: 22614020
[TBL] [Abstract][Full Text] [Related]
18. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.
Dibra D; Mitra A; Newman M; Xia X; Cutrera JJ; Gagea M; Kleinerman ES; Lozano G; Li S
Clin Cancer Res; 2016 Aug; 22(15):3876-83. PubMed ID: 26979394
[TBL] [Abstract][Full Text] [Related]
19. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice.
Wikonkal NM; Remenyik E; Knezevic D; Zhang W; Liu M; Zhao H; Berton TR; Johnson DG; Brash DE
Nat Cell Biol; 2003 Jul; 5(7):655-60. PubMed ID: 12833065
[TBL] [Abstract][Full Text] [Related]
20. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
